Om

Active Biotech AB is a Swedish biotechnology company focused on developing pharmaceutical products that modulate the immune system. Headquartered in Lund and founded in 1983, the company concentrates on treatments for cancer and inflammatory diseases, particularly inflammatory eye disorders. Its current portfolio centers on three key projects: Tasquinimod, a small-molecule immunomodulator studied in multiple myeloma; Laquinimod, aimed at inflammatory eye conditions such as uveitis; and Naptumomab, an antibody-based immunotherapy targeting solid tumors. Active Biotech operates in the research and development segment of the healthcare market, working primarily through clinical-stage collaborations and licensing arrangements with larger pharmaceutical partners. By focusing on specialist indications with significant unmet medical need, the company plays a niche role within the global biopharmaceutical ecosystem, contributing novel immune-modulating therapies that may complement existing oncology and immunology treatment paradigms.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I ACTIVE BIOTECH MED ENDAVU: Køb Active Biotech ($BTP) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Active Biotech, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.